Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Current Assets: 2009-2024

Historic Current Assets for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $1.1 billion.

  • Cytokinetics' Current Assets fell 4.05% to $977.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $977.3 million, marking a year-over-year decrease of 4.05%. This contributed to the annual value of $1.1 billion for FY2024, which is 76.41% up from last year.
  • Cytokinetics' Current Assets amounted to $1.1 billion in FY2024, which was up 76.41% from $628.1 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Current Assets registered a high of $1.1 billion during FY2024, and its lowest value of $474.2 million during FY2020.
  • Moreover, its 3-year median value for Current Assets was $795.2 million (2022), whereas its average is $843.7 million.
  • Per our database at Business Quant, Cytokinetics' Current Assets spiked by 102.87% in 2020 and then declined by 21.02% in 2023.
  • Over the past 5 years, Cytokinetics' Current Assets (Yearly) stood at $474.2 million in 2020, then grew by 12.96% to $535.7 million in 2021, then surged by 48.45% to $795.2 million in 2022, then fell by 21.02% to $628.1 million in 2023, then soared by 76.41% to $1.1 billion in 2024.